

## **INTERIM ACS STEMI Alteplase**

	<b>Services</b>	5	Timomborye	510 <b>0</b> 1 4010			ace	Ldi	bei	пег	e
		Allergies:									
Ht.	cm										
Wt	kg	Diagnosis: Acute	Coronary Syndrome								
Da	te (yyyy-Mon-a	ld)	Time	Physician C	Orders	C P	C E	R	M P	M R	Sign
		GRACE	Score (risk)								
			or transfer to								
				-							
1	the 2 sides		•	20 mm ig amereno.	o botween						
				l, q4h x 12 h, TID a	nd prn						
• (	CBC, PT, PT	Γ, ALT, creatinine, ele									
	-		es glucose on Day 2 (	Presentation to FD	is Day ())						
	<b>Tnl</b> at 6 – 8 h	☐ <b>Tnl</b> at 18	3 – 24 h								
			ofile (do within 24 h af	ter a 10 –12 h fast)							
	•	oelic)									
		eat at 45 min, 60 min,	90 min: then daily x 3	(and prn with ches	st pain						
,	and/or signif	icant arrhythmias)	·		•						
•		•	ready given) Given at _	n							
	the state of the s										ion
	——————————————————————————————————————				0.5 111						0 min
	Given at	n			Giver						
	-		<b>.</b>								
i				o of altenlace			30	mg	y IV	bolu	ıs
					give		Gi	ven	at _		h
	Enoxa	oarin <b>1 mg/kg</b> deep s	ubcutaneous ( <i>Max</i> . 10	00 mg/dose for first	2 doses; <b>n</b>	ot	Ву	<b>/</b> :			
	☐ 75 years	and older and eGFI	R at least 30 mL/min:								
	• 0.75 m	g/kg deep subcutane		of initiating alteplas	se infusion	and	1 <sup>S</sup>	<sup>t</sup> do	se =	=	
		· ·		tion atout because							
Htcm   Line   Company   Diagnosis: Acute Coronary Syndrome   Company   Date   (yyyy-Mon-dd)   Time   Physician Orders   Company   Date   (yyyy-Mon-dd)   Time   Physician Orders   Company   Date   Date						h					
•	Reassess at	48 h re: Continuation	of therapy				Ву	<b>/</b> :			
OR		≺ 30 - 60 mL/min <i>(</i> Se	e reverse)			<del></del>					
_	IV heparin as					ss					
Ph	ysician Signa		CLacorrio manimont o	g., siocally lion	/				Pan		of 3
	, 5.9								ay	ا ت	UI J

Enoxaparin — Beyond 48h, may consider reducing dose; CrCl 40 - 60 mL/min, consider 0.75 mg/kg q12h; CrCl 10 - 39 mL/min, consider 1 mg/kg q24h or 0.5 mg/kg q12h. If eatment continues beyond 5 - 7 days, further adjustment may be onsidered in patients with CrCl less than 80 mL/min.  (Br J Clin Pharmacol 2004;59:281-90.)  Administer using a # 27 needle, do not flush air out of needle, and inject over more than 30 seconds.  Use antero / lateral abdomen (not muscle), maximum 1 mL per injection site						
<ul> <li>Indications for Thrombolysis</li> <li>Ischemic chest pain (more than 20 min; less than 6 - 12 h) not relieve</li> <li>ST elevation of 1 mm or greater in at least</li> </ul>	□ Yes □ No	nin in the ED				
<ul> <li>2 contiguous precordial leads</li> <li>2 adjacent limb leads OR</li> <li>New or presumed new LBBB OR</li> <li>Findings consistent with true posterior MI</li> <li>Assess patients individually with continuous symptoms of 12 - 24 and appropriate ECG criteria</li> </ul>	☐ Yes ☐ No					
Note: For patients in severe heart failure or cardiogenic shock, eme Target time for PCI is 60 min (door to PCI time 90 min), except it						
<u>Contraindications</u>						
Absolute     Any prior ICH (intracranial hemorrhage)     Known structural cerebral vascular lesions (e.g. AVM)     Known primary or secondary CNS neoplasm     Ischemic stroke in last 3 - 6 months (except acute ischemia strok     Aortic dissection (Right versus Left arm systolic BP greater than     Active bleeding or bleeding diathesis (excluding menses)     Significant closed head or facial trauma within 3 months     Acute pericarditis  Relative	e within 3 h) 15 mm Hg difference)	□ Yes □ No				
<ul> <li>Severe uncontrolled HTN (systolic greater than 180, diastolic gre</li> <li>Traumatic or prolonged CPR (greater than or equal to 10 min)</li> <li>Recent (within 2 - 6 weeks) major trauma, surgery (including lase</li> <li>Pregnancy or postpartum state</li> <li>Prior stroke greater than 3 months old, dementia, or other intracra</li> <li>Non compressible vascular puncture</li> <li>Bleeding or clotting problems, on anticoagulants</li> </ul>	er eye surgery), GI/GU bleed	☐ Yes ☐ No				

TIMI Risk Score for STEMI					
Historical	Points				
Age					
75 or older	3				
65 - 74	2				
DM or HTN or angina	1				
Exam					
SBP less than 100 mmHg	3				
HR greater than 100 bpm	2				
Killip II-IV	2				
Weight less than 67 kg (150 lb)	1				
Presentation					
Anterior STE or LBBB	1				
Time to Rx more than 4 h	1				
Risk Score = Total points (0 - 14)					


GRACE ACS Risk Model

http://www.outcomesumassmed.org/GRACE/ acs\_risk.cfm


Use "Web Version" to do calculation

## Killip Class:

- 1 = no signs of heart failure
- 2 = basal crackles (mild pulmonary congestion)
   S3, ↑ JVP
- 3 = extensive crackles
  - 4 = cardiogenic shock (systolic BP less than 90 mm Hg, hypoperfusion)



TIMI risk score for STEMI for predicting 30-day mortality. STE indicates ST elevation; h/o, history of.



TIMI risk score for STEMI for predicting 1-year mortality (30-day survivors)



## **INTERIM ACS STEMI Alteplase Thrombolysis Orders**

Place Label Here

	Allergies:									
Ht cm	_									
Wt kg	Diagnosis:	Acute Coronary Syndrome								
Date (yyyy-Mon-d	d)	Time	Physician Orders	(	C P	C E	R	M P	M R	Sign
<ul> <li>No unnecessary arterial or venous punctures x 24 h</li> <li>No IM injections x 24 h</li> <li>Apply pressure dressing to potential source of bleeding, including old venous or arterial punctures</li> <li>Alert physician if signs of bleeding, dysrhythmias, or abnormal vital signs or has persistent pain for 30 min or longer</li> <li>Medications</li> <li>Clopidogrel (up to age 75) 300 mg PO now and then 75 mg PO daily</li> <li>Clopidogrel (age 75 and older) 75 mg PO now and then 75 mg PO daily</li> <li>ACE Inhibitor / ARB</li> <li>B-Blocker</li> <li>Statin</li> <li>Vasopressor</li> <li>Nitroglycerin IV (50 mg in 250 mL D5W) at 10 mcg/min; increase by 5 - 10 mcg/min q5 - 10 min for pain control (maximum 200 mcg/min); maintain systolic BP greater than 90 mm 3Hg</li> <li>OR</li> <li>Nitroglycerin Patch</li> <li>mg/h (on 12 h, off 12 h)</li> <li>Nicotine Replacement</li> <li>Ranitidine 150 mg PO BID</li> </ul>										
unit: unit: unit:	s SC for CBC s SC for CBC s SC for CBC s SC for CBC	for QID capillary k	plood glucose <i>(CBG)</i> values							
Other Medicatio	ns /Orders					F	• •	e 2	of 3	

Date (yyyy-Mon-dd)	Time	Physician Orders	C P	C E	R	M P	M R	Sign
<ul> <li>Medications</li> <li>Docusate Sodium 100 mg PO bid</li> <li>Acetaminophen 325 - 650 mg PO q4h prn</li> <li>Antacid 30 mL PO prn</li> <li>Dimenhydrinate (Gravol®) 50 mg PO, PR or IV q4h prn and/or Metoclopramide (Maxeran®) 10 mg IV q6h prn</li> <li>Lorazepam 0.5 – 1 mg sublingual tid and hs prn</li> <li>Sennosides 8.6 mg; 2 tabs PO qhs prn</li> <li>Nitroglycerin spray 0.4 mg sublingual q5 minutes x 3 prn</li> <li>Zopiclone 7.5 mg PO qhs prn</li> <li>Morphine 2 - 5 mg IV prn if no relief with nitroglycerin spray (maximum 20 mg/h)</li> </ul>								
<ul> <li>If allergic to morphine give</li> <li>Fentanyl 25 - 50 mcg IV prr</li> <li></li></ul>	n (maximum 300 mcg/f	,						
Diet: ☐ Cardiac ☐ Diabetic - No Added Sugar ☐ Renal  Cardiac teaching  Referrals ☐ Pharmacist re: ☐ ☐ Dietitian ☐ Cardiac Rehab ☐ Other:								
☐ Capillary blood glucose QIE	)							
□ Echocardiogram □ Cardiac Catheterization								
•								
Activity     Start at activity level A and daily     If experiencing chest discornew arrhythmias, hold at culevel and alert physician of symptoms     Keep a copy of activity leve bedside	A: Bedres B: Chair - bedside C: Walk in bedside D: Walk o Progres period	ach level is one day t; commode chair progress from 15 - 30 min; wash at e; commode chair room and bathroom; wash at e or washroom utside room for 1- 2 min periods. as to 5 min 2 - 3 times/day; rest for n a.m. and p.m.; shower after ing with physician/nurse						
Physician Signature	ysician Signature				Pa	age :	3 of	3

The information contained in this document, and as amended from time to time, was created expressly for use by Alberta Health Services and persons acting on behalf of the Alberta Health Services for guiding actions and decisions taken on behalf of Alberta Health Services. Any adoption/use/modification of this document is done so at the risk of the adopting organization. Alberta Health Services accepts no responsibility for any modification and/or redistribution and is not liable in any way for any actions taken by individuals based on the information herein, or for any inaccuracies, errors, or omissions in the information in this document.

## Table A. Alteplase (Activase ®) 1 mg/mL Dosage and Electronic Infusion Device Settings

• Using the diluent provided, reconstitute one alteplase 100 mg or two alteplase 50 mg vials to create a final concentration of alteplase 1 mg/ml. Dissolve (DO NOT SHAKE vigorously) - turn vial over and allow to mix

Patient Weight (kg)	Administration Option: Place volume of first plus second infusion into buretrol, glass vial or empty PVC bag (mL) for administration after initial bolus	Specific Dosages  Administered as a 15 mg bolus dose followed by a 30 minute infusion then a 60 minute infusion	Infusion Rate Setting (mL/hr)	Volume to be infused (mL)	Total Dose (mg) (Bolus + Maintenance) 1 mg=1 mL
41-42	52	Bolus: 15 mg (15 mL) IV over 2 minutes     First Infusion: 31 mg (31 mL) IV over 30 minutes     Second Infusion: 21 mg (21 mL) IV over 60 minutes	62 21	31 21	67
43-44	54	Bolus: 15 mg (15 mL) IV over 2 minutes     First infusion: 32 mg (32 mL) IV over 30 minutes     Second Infusion: 22 mg (22 mL) IV over 60 minutes	64 22	32 22	69
45-47	57	Bolus: 15 mg (15 mL) IV over 2 minutes     First infusion: 34 mg (34 mL) IV over 30 minutes     Second Infusion: 23 mg (23 mL) IV over 60 minutes	68 23	34 23	72
48-49	60	Bolus: 15 mg (15 mL) IV over 2 minutes     First infusion: 36 mg (36 mL) IV over 30 minutes     Second infusion: 24 mg (24 mL) IV over 60 minutes	72 24	36 24	75
50-51	63	Bolus: 15 mg (15 mL) IV over 2 minutes     First infusion: 38 mg (38 mL) IV over 30 minutes     Second infusion: 25 mg (25 mL) IV over 60 minutes	75 25	38 25	78
52-54	65	Bolus: 15 mg (15 mL) IV over 2 minutes     First infusion: 39 mg (39 mL) IV over 30 minutes     Second infusion: 26 mg (26 mL) IV over 60 minutes	78 26	39 26	80
55-56	68	Bolus: 15 mg (15 mL) IV over 2 minutes     First infusion: 41 mg (39 mL) IV over 30 minutes     Second infusion: 27 mg (26 mL) IV over 60 minutes	82 27	41 27	83
57-58	71	1, Bolus: 15 mg (15 mL) IV over 2 minutes 2. First infusion: 43 mg (43 mL) IV over 30 minutes 3, Second infusion: 28 mg (28 mL) IV over 60 minutes	86 28	43 28	86
59-60	73	Bolus: 15 mg (15 mL) IV over 2 minutes     First infusion: 44 mg (44 mL) IV over 30 minutes     Second infusion: 29 mg (29 mL) IV over 60 minutes	88 29	44 29	88
61-63	76	Bolus: 15 mg (15 mL) IV over 2 minutes     First infusion: 46 mg (46 mL) IV over 30 minutes     Second infusion: 30 mg (30 mL) IV over 60 minutes	92 30	46 30	91
64-65	80	Bolus: 15 mg (15 mL) IV over 2 minutes     First infusion: 48 mg (48 mL) IV over 30 minutes     Second infusion: 32 mg (32 mL) IV over 60 minutes	96 32	48 32	95
66-67	83	Bolus: 15 mg (15 mL) IV over 2 minutes     First infusion: 50 mg (50 mL) IV over 30 minutes     Second infusion: 33 mg (33 mL) IV over 60 minutes	100 33	50 33	98
		1. Bolus: 15 mg (15 mL) IV over 2 minutes			

Your existing STEMI order set containing tenecteplase (TNK) is the "backbone" document for using alteplase as the thrombolytic during the TNK backorder situation. An alteplase protocol was developed and has had input from pharmacy, nursing and physician stakeholders.

The alteplase protocol will result in some changes that front line staff needs to be aware of.

**EXAMPLE** DTHR – using Form 08912 ACS STEMI Thrombolysis Orders, there are eleven changes to note:

Change	New	Replaces	
1. Title of Order Set (header)	INTERIM ACS STEMI Alteplase Thrombolysis Orders	ACS STEMI Thrombolysis Orders	
2. Title of Order Set (footer)	INTERIM ACS STEMI Alteplase Thrombolysis Orders	ACS STEMI Thrombolysis Orders	
3. Alteplase BOLUS dose	Alteplase BOLUS dose 15 mg/15 mL IV bolus over 2 minutes Given ath By:	Tenecteplase bolus instructions (left box)	
4. Alteplase FIRST infusion	Alteplase FIRST infusion 0.75 mg/kg from Table Amg infusion over 30 min Given ath By:	Tenecteplase dosing information (middle box)	
5. Alteplase SECOND infusion	Alteplase SECOND infusion 0.5 mg/kg from Table Amg infusion over 60 min Given ath By:	Tenecteplase dosing information (right box)	
6. Enoxaparin dosing for less than 75 years and eGFR at least 30 mL/min – bolus dose	Enoxaparin dosing for less than 75 years and eGFR at least 30 mL/min – 30 mg IV bolus immediately prior to administration of alteplase	Enoxaparin dosing for less than 75 years and eGFR at least 30 mL/min – 30 mg IV bolus immediately after TNK	
7. Enoxaparin dosing for less than 75 years and eGFR at least 30 mL/min – follow-up doses	Enoxaparin dosing for less than 75 years and eGFR at least 30 mL/min – (subcutaneous dosing) within 30 minutes of initiating alteplase infusion	Enoxaparin dosing for less than 75 years and eGFR at least 30 mL/min – (subcutaneous dosing) 15 minutes after [TNK] bolus and then q12h	
8. Enoxaparin dosing for 75 years and older and eGFR at least 30 mL/min	0.75 mg/kg deep subcutaneous within 30 minutes of initiating alteplase infusion and then q12h	0.75 mg/kg deep subcutaneous immediately after TNK and then q12h	
9. eGFR 10-29 mL/min	Regardless of age use unfractionated heparin	Regardless of age, immediately after TNK 1 mg/kg deep subcutaneous and q24h (Max 100 mg/dose for first 2 doses)	
10. IV heparin	For severe renal failure with eGFR less than 30 mL/min	For severe renal failure with eGFR less than 10 mL/min	
11. Table A	Table A – provides weight based dosing of bolus, FIRST infusion and SECOND infusion and rates as well as optional buretrol volume information	Was not in the old form	

The information contained in this document, and as amended from time to time, was created expressly for use by Alberta Health Services and persons acting on behalf of the Alberta Health Services for guiding actions and decisions taken on behalf of Alberta Health Services. Any adoption/use/modification of this document is done so at the risk of the adopting organization. Alberta Health Services accepts no responsibility for any modification and/or redistribution and is not liable in any way for any actions taken by individuals based on the information herein, or for any inaccuracies, errors, or omissions in the information in this document.